Updates are available Correction dated 2024-03-13
Click to view Correction: https://doi.org/10.1007/s12325-024-02831-y
-
Authors
Watkins, Claire
Paulo, Tatiana
Bührer, Christian https://orcid.org/0009-0007-9006-8787
Holekamp, Nancy M.
Bagijn, Marloes
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche
- License Information
-
More Information
Article History
Received: 19 July 2023
Accepted: 31 August 2023
First Online: 26 September 2023
Change Date: 13 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-024-02831-y
Declarations
:
: Tatiana Paulo, Marloes Bagijn and Christian Bührer are employees of F. Hoffmann-La Roche Ltd. Claire Watkins is an employee of Clarostat Consulting Ltd, which was contracted by F. Hoffmann-La Roche to undertake the data analysis for this study. Nancy M. Holekamp has served as a consultant for Acucela, Allergan, Apellis, Bayer, Clearside Biosciences, Gemini, Genentech, Inc., Gyroscope, Katalyst Surgical, Lineage Cell Therapeutics, Nacuity, Notal Vision, Novartis, PolyActiva, and Regeneron, and is currently a visiting professor at F. Hoffmann-La Roche Ltd.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
